Sign Out
Clinically significant adverse reactions: Hypoglycemia (frequency unknown): Hypoglycemia may occur. If the patient develops hypoglycemia, glucose should be administered promptly by intravenous infusion. In addition, appropriate nutrition management is recommended in such patients.
Hyperammonemia (frequency unknown): Hyperammonemia has been reported. If the patient develops persistent hyperammonemia during the administration of Amino Acids (AMINOLEBAN), discontinue administration of nitrogen sources including Amino Acids (AMINOLEBAN) and institute appropriate measures.
Other adverse reactions: If adverse reactions are observed, discontinue the administration, and institute appropriate treatment. (See Table 3.)
Click on icon to see table/diagram/image
View ADR Reporting Link
Continue with Google